A pharmaceutical composition comprising: a) a compound A, which is (2 R)-2-(4-fluorophenyl)- N -[4-(2-{[2-methoxy-4-(methylsulfonyl)phenyl]amino}[1,2,4]triazolo[1,5- a]pyridin-6-yl)phenyl]propanamide, or a salt, hydrate or solvate thereof; and b1) a matrix B1, said matrix B1 consisting of i. 70% to 100% by weight of polyethylene glycol having an average molecular weight of from 100 to 800; ii. 0% to 30% by weight of polyvinylpyrrolidone; and iii. 0% to 10% by weight of water; and iv. 0% to 5% by weight of one or more pharmaceutically acceptable excipients; wherein the weight ratio of the compound A calculated as a solvent-free base to the matrix B1 is smaller than 20: 80; or b2) a matrix B2, said matrix B2 consisting of i. 40% to 60% by weight of polyvinylpyrrolidone ii. 40% to 60% by weight of croscarmellose sodium; and iii. 0% to 5% by weight of one or more pharmaceutically acceptable excipients; wherein the weight ratio of the compound A calculated as a solvent-free base to the matrix B2 is smaller than 20: 80; or b3) a matrix B3, said matrix B3 consisting of i. 95% to 100% by weight of a polyethylene glycol having an average molecular weight of from 4000 to 8000; and ii. 0% to 5% by weight of one or more pharmaceutically acceptable excipients; wherein the weight ratio of the compound A calculated as a solvent-free base to the matrix B3 is smaller than 30: 70. a) a compound A, which is (2 R)-2-(4-fluorophenyl)- N -[4-(2-{[2-methoxy-4-(methylsulfonyl)phenyl]amino}[1,2,4]triazolo[1,5- a]pyridin-6-yl)phenyl]propanamide, or a salt, hydrate or solvate thereof; and b1) a matrix B1, said matrix B1 consisting of i. 70% to 100% by weight of polyethylene glycol having an average molecular weight of from 100 to 800; ii. 0% to 30% by weight of polyvinylpyrrolidone; and iii. 0% to 10% by weight of water; and iv. 0% to 5% by weight of one or more pharmaceutically acceptable excipients; wherein the weight ratio of the compound A calculated as a solvent-free base to the matrix B1 is smaller than 20: 80; or i. 70% to 100% by weight of polyethylene glycol having an average molecular weight of from 100 to 800; ii. 0% to 30% by weight of polyvinylpyrrolidone; and iii. 0% to 10% by weight of water; and iv. 0% to 5% by weight of one or more pharmaceutically acceptable excipients; b2) a matrix B2, said matrix B2 consisting of i. 40% to 60% by weight of polyvinylpyrrolidone ii. 40% to 60% by weight of croscarmellose sodium; and iii. 0% to 5% by weight of one or more pharmaceutically acceptable excipients; wherein the weight ratio of the compound A calculated as a solvent-free base to the matrix B2 is smaller than 20: 80; or i. 40% to 60% by weight of polyvinylpyrrolidone ii. 40% to 60% by weight of croscarmellose sodium; and iii. 0% to 5% by weight of one or more pharmaceutically acceptable excipients; b3) a matrix B3, said matrix B3 consisting of i. 95% to 100% by weight of a polyethylene glycol having an average molecular weight of from 4000 to 8000; and ii. 0% to 5% by weight of one or more pharmaceutically acceptable excipients; wherein the weight ratio of the compound A calculated as a solvent-free base to the matrix B3 is smaller than 30: 70. i. 95% to 100% by weight of a polyethylene glycol having an average molecular weight of from 4000 to 8000; and ii. 0% to 5% by weight of one or more pharmaceutically acceptable excipients;